Charlotte Lohmann
Direktor/Vorstandsmitglied bei VIVORYON THERAPEUTICS N.V.
Ursprung des Netzwerks ersten Grades von Charlotte Lohmann
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
Ludwig-Maximilians-Universität München
55
| College/University | Other Consumer Services | 55 |
55
| Public Company | Biotechnology | 55 |
| Public Company | Biotechnology | 22 | |
| Public Company | Pharmaceuticals: Major | 14 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Charlotte Lohmann
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| MERCK KGAA | Pharmaceuticals: Major | Corporate Officer/Principal Director of Finance/CFO Corporate Officer/Principal Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| Swiss Federal Institute of Technology | College/University | Graduate Degree Doctorate Degree Corporate Officer/Principal Doctorate Degree | |
| 4SC AG | Biotechnology | Chairman Director/Board Member Chief Executive Officer | |
F. Hoffmann-La Roche Ltd.
 F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| IMMATICS N.V. | Biotechnology | Director/Board Member Director/Board Member Corporate Officer/Principal | |
Immatics US, Inc.
 Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX. | Biotechnology | Director/Board Member Director/Board Member Chief Tech/Sci/R&D Officer | |
| SIEMENS AG | Industrial Machinery | Chief Tech/Sci/R&D Officer Comptroller/Controller/Auditor Public Communications Contact | |
| NOVARTIS AG | Pharmaceuticals: Major | Director/Board Member Public Communications Contact Chief Tech/Sci/R&D Officer | |
| MEDIGENE AG | Biotechnology | Founder Director of Finance/CFO Director/Board Member | |
Immatics Biotechnologies GmbH
 Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Corporate Officer/Principal | |
Roche Diagnostics GmbH
 Roche Diagnostics GmbH Miscellaneous Commercial ServicesCommercial Services Part of Roche Holding AG, Roche Diagnostics GmbH is a German company that develops innovative medicines, treatments, and diagnostics. The company is based in Mannheim, Germany. The CEOs of the company are Claudia Fleischer, Claus Haberda, Clemens Schmid. Roche Diagnostics was acquired by Roche Holding AG on January 01, 1999. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
Vectura GmbH
 Vectura GmbH Medical SpecialtiesHealth Technology Vectura GmbH manufactures and develops pharmaceutical therapies for airways diseases. It offers dry powder formulation technology, device technology, and development capabilities. The company was founded by Gerhard Scheuch in 1997 and is headquartered in Gemünden, Germany. | Medical Specialties | Director/Board Member Corporate Officer/Principal Corporate Officer/Principal | |
Ventaleon GmbH
 Ventaleon GmbH Pharmaceuticals: OtherHealth Technology Ventaleon GmbH is a biotechnology company, which engages in the development of inhaled treatments against viral infections. Its products include LASAG (D,L-lysine acetylsalicylate • glycine), a lysin-salt formulation of well known acetyl salicylic acid. The company was founded by Gerhard Scheuch in 2012 and is headquartered in Gauting, Germany. | Pharmaceuticals: Other | Director/Board Member Director/Board Member Chief Executive Officer | |
CureVac SE
 CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
| Humboldt-Universität zu Berlin | College/University | Corporate Officer/Principal Undergraduate Degree Graduate Degree | |
| Technische Universität München | College/University | Doctorate Degree Doctorate Degree Doctorate Degree | |
| 2INVEST AG | Financial Conglomerates | Director/Board Member Director/Board Member Director/Board Member | |
febit holding GmbH
 febit holding GmbH Medical/Nursing ServicesHealth Services febit holding GmbH engages in the design and development of technologies used for DNA analysis. It specializes in technologies with applications in genomic research, RNA expression profiling, and other diagnostic and molecular biology fields. The company was founded by Markus Beier, Ramon Gueimil, Peer F. Staehler, Matthias Scheffler, and Cord F. Stähler in 2005 and is headquartered in Heidelberg, Germany. | Medical/Nursing Services | Director/Board Member Director/Board Member Chairman | |
| Freie Universität Berlin | College/University | Doctorate Degree Doctorate Degree Graduate Degree | |
Molecular Health, Inc.
 Molecular Health, Inc. Packaged SoftwareTechnology Services Molecular Health, Inc. operates as a cloud-based healthcare decision support technology to enable evidence-based treatment decisions. The company was founded in 2004 and is headquartered in Boston, MA. | Packaged Software | Chairman Director/Board Member | |
| ALLIANZ SE | Multi-Line Insurance | Corporate Officer/Principal Corporate Officer/Principal | |
| GRENKE AG | Finance/Rental/Leasing | Investor Relations Contact Director/Board Member | |
| University of Wisconsin | College/University | Doctorate Degree Masters Business Admin | |
| Fachhochschule Ludwigshafen am Rhein | College/University | Corporate Officer/Principal Undergraduate Degree | |
| CUREVAC N.V. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
| Martin-Luther-Universität Halle-Wittenberg | College/University | Undergraduate Degree Doctorate Degree | |
| Karlsruher Institut für Technologie | College/University | Undergraduate Degree Chief Tech/Sci/R&D Officer | |
| The Johannes Gutenberg University of Mainz | College/University | Doctorate Degree Doctorate Degree | |
| Universität zu Köln | College/University | Graduate Degree Doctorate Degree | |
dievini Hopp BioTech holding GmbH & Co. KG
 dievini Hopp BioTech holding GmbH & Co. KG Investment ManagersFinance dievini Hopp BioTech holding GmbH & Co. KG operates as a private investment and consulting firm. It invests in companies related to the life and health sciences. It focuses with companies that diagnoses and provides therapy in the fields of oncology, neurology, infectious diseases, cell therapy and drug delivery systems. The company is headquartered in Walldorf, Germany. | Investment Managers | Private Equity Investor Founder | |
| Friedrich-Alexander University of Erlangen-Nuremberg | College/University | Undergraduate Degree Corporate Officer/Principal | |
| dievini Verwaltungs GmbH | Chief Executive Officer Chief Executive Officer | ||
| AC IMMUNE SA | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| SEMPERIT AG HOLDING | Building Products | Director of Finance/CFO Director/Board Member | |
Syntimmune, Inc.
 Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | Biotechnology | Director/Board Member President | |
Molecular Health GmbH
 Molecular Health GmbH Miscellaneous Commercial ServicesCommercial Services Part of Posbelduf Biotech AG, Molecular Health GmbH is a German management consulting company. The company is based in Heidelberg, Germany. The company was founded in 2004 by Friedrich von Bohlen und Halbach. Friedrich von Bohlen und Halbach has been the CEO since 2004. | Miscellaneous Commercial Services | Chief Executive Officer Chairman | |
| Febit, Inc. | Director/Board Member Chairman | ||
| ILLUMINA, INC. | Biotechnology | Director/Board Member Director/Board Member | |
| BAYER AG | Pharmaceuticals: Major | Director of Finance/CFO Director/Board Member | |
| ROCHE HOLDING AG | Pharmaceuticals: Major | Sales & Marketing Public Communications Contact | |
Hoffmann-La Roche, Inc.
 Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Biotechnology | Sales & Marketing Corporate Officer/Principal |
Statistik
International
| Deutschland | 36 |
| Vereinigte Staaten | 9 |
| Schweiz | 5 |
| Vereinigtes Königreich | 2 |
| Japan | 2 |
Sektoral
| Health Technology | 24 |
| Consumer Services | 12 |
| Commercial Services | 7 |
| Finance | 5 |
| Producer Manufacturing | 3 |
Operativ
| Director/Board Member | 360 |
| Chief Executive Officer | 207 |
| Corporate Officer/Principal | 191 |
| Chairman | 124 |
| Independent Dir/Board Member | 68 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Helene von Roeder | 84 |
| Christof Hettich | 40 |
| George Golumbeski | 36 |
| Friedrich von Bohlen und Halbach | 36 |
| Jörg Neermann | 34 |
| Daniel Camus | 31 |
| Erich Maximilian Platzer | 31 |
| Christian Rudolf Näther | 30 |
| Gerald Heinz Möller | 29 |
| Karin Eastham | 29 |
| Marcus Englert | 28 |
| Wendy Johnson | 23 |
| Thomas D. Szucs | 23 |
| Marion Weissenberger-Eibl | 22 |
| Frank Morich | 21 |
- Börse
- Insiders
- Charlotte Lohmann
- Unternehmensverbindungen
